Woodham Lane, New Haw, Addlestone, Surrey KT15 3LS Telephone +44 (0)1932 336911

Post Authorisation Assessments

Heptavac P Plus Vm 01708/5099

•	May 2024	To align the product information with the version 9.0 of
		the SPC/QRD templates.
•	24 October 2023	Change to comply with Ph. Eur.
•	30 June 2023	To update of the sterility test procedure performed on the finished product according to Ph.Eur. 2.6.1. Minor adjustments to the method suitability test to improve recovery of the A. brasiliensis reference strain.
•	17 April 2023	Addition of an in vitro potency ELISA for C. perfringens type C beta toxoid. Optimisation of the statistical analysis method for the Fab ELISA to confirm M. haemolytica identity and P. trehalosi identity/potency. Addition of Intervet International B.V., Boxmeer, NL, as finished product Quality Control test site for the C. perfringens type C beta toxoid potency test, M. haemolytica identity test and P. trehalosi identity/potency test.
•	05 April 2023	Addition of an in vitro toxicity test for C. chauvoei cells and toxoid. Addition of the use of bovine liver extract in Clostridia growth medium.
•	20 February 2023	Addition of an in vitro toxicity test for C. chauvoei cells and toxoid. Addition of the use of bovine liver extract in Clostridia growth medium.
•	24 June 2022	Change of a test procedure for the active substance. Change of a test procedure for the active substance. Change of a test procedure for the active substance.
•	16 June 2022	Changes to a test procedure for the finished product.
•	16 February 2022	Change to a test procedure (including replacement or addition) for the active substance. Change in the manufacturing process of the active substance. Change in the manufacturing process of the active substance. Change in the manufacturing process of the active substance. Change in the manufacturing process of the active substance. Change in the manufacturing process of the active substance. Change in the manufacturing process of the active substance. Change in the manufacturing process of the active substance. Change in the manufacturing process of the active

		substance.
•	05 October 2021	Update of the test procedure to comply with the updated
		general Ph. Eur monograph.
		Minor changes to an approved test procedure of the
		finished product.
		Minor changes to an approved test procedure of the
		finished product. Changes to a test procedure for the finished product.
		Changes to a test procedure for the finished product. Changes to a test procedure for the finished product.
		Changes to a test procedure for the finished product. Changes to a test procedure for the finished product.
		Changes to a test procedure for the finished product.
		Changes to a test procedure for the finished product.
		Addition of a site where batch control/testing takes place.
•	07 September 2021	Summary of Product Characteristics and product
		literature updated with regard to pharmacovigilance data.
•	15 June 2021	Change in the manufacturing process of the finished
	44 1 0004	product.
•	11 January 2021	Changes to the labelling and/or package leaflet.
•	01 October 2020	Change in the name of a manufacturer of the finished product, also responsible for batch release.
•	11 September 2020	Change in the name of a manufacturer used in the
		manufacture of the active substance.
•	14 August 2020	Change in the name of the marketing authorisation
		holder from Intervet UK Limited to MSD Animal Health
_	26 April 2010	UK Limited.
•	26 April 2019	Addition of a manufacturer responsible for batch release of the finished product.
•	18 May 2018	Change in the manufacturing process of the active
	10 may 2010	substance.
		Change in the manufacturing process of the active
		substance.
•	01 May 2018	Change in RMS from UK to IT.
•	01 November 2016	Change in name of manufacturer of the active
	20.5	substance.
•	02 December 2015	Change in the specification parameters and/or limits of
_	08 November 2012	the finished product Change to manufacturing process of an active substance
•	OO NOVEIIIDEI ZUIZ	Change to manufacturing process of an active substance
•	30 March 2012	Change of name of manufacturer of the finished product
•	14 July 2010	Update of detailed description of manufacturing process
•	01 September 2009	Change of address of MAH in Portugal only
•	02 April 2008	Renewal
•	13 October 2006	Change to manufacturing process of the active
		substance
•	20 May 2005	Change of distributor
•	17 January 2005	Change to test procedure performed on a starting
	40 1.1. 0004	material used in the manufacture of the active substance
•	12 July 2004	Repeat use
•	19 March 2004	Updates to the SPC
•	07 May 2003	Renewal
•	13 November 2002	Change to specification of the finished product
•	10 September 2002	Addition of 2 manufacturing sites for labelling and

	1	
		packaging
		Change to shape of packaging
•	31 January 2002	Change of supplier of a reagent used in the production of
	•	the finished product
•	07 November 2001	Change to the manufacturing process of the active
		substance
•	31 August 2001	Addition of a distributor
•	11 May 2001	Change of product name from 'Heptavac P New' to
		'Heptavac P Plus'
•	09 February 2001	QC Procedures
•	08 February 2001	Change to manufacturer of the active substance
•	01 August 2000	Change to specification of the active substance
•	31 March 2000	Change of name and address of the MAH
•	29 March 2000	Change to specification of the active substance
•	29 October 1999	Change of shelf life from 12 months to 24 months
		Change to manufacturing process of the active
		substance
		Change of product formulation
		Change to QC procedures
•	31 December 1998	Minor change in manufacturing procedure of the active
		substance